210 related articles for article (PubMed ID: 24513177)
1. 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
Al-Rayyan N; Litchfield LM; Ivanova MM; Radde BN; Cheng A; Elbedewy A; Klinge CM
Cancer Lett; 2014 May; 347(1):139-50. PubMed ID: 24513177
[TBL] [Abstract][Full Text] [Related]
2. COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells.
Litchfield LM; Appana SN; Datta S; Klinge CM
Mol Cell Endocrinol; 2014 Jan; 382(1):358-367. PubMed ID: 24141032
[TBL] [Abstract][Full Text] [Related]
3. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells.
Litchfield LM; Riggs KA; Hockenberry AM; Oliver LD; Barnhart KG; Cai J; Pierce WM; Ivanova MM; Bates PJ; Appana SN; Datta S; Kulesza P; McBryan J; Young LS; Klinge CM
PLoS One; 2012; 7(5):e38278. PubMed ID: 22693611
[TBL] [Abstract][Full Text] [Related]
5. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Bovenzi V; Momparler RL
Cancer Chemother Pharmacol; 2001 Jul; 48(1):71-6. PubMed ID: 11488527
[TBL] [Abstract][Full Text] [Related]
7. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
8. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
10. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
11. Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression.
Nagasaki S; Suzuki T; Miki Y; Akahira J; Shibata H; Ishida T; Ohuchi N; Sasano H
Cancer Sci; 2009 Apr; 100(4):639-45. PubMed ID: 19154418
[TBL] [Abstract][Full Text] [Related]
12. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
13. Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Ammanamanchi S; Kim SJ; Sun LZ; Brattain MG
J Biol Chem; 1998 Jun; 273(26):16527-34. PubMed ID: 9632722
[TBL] [Abstract][Full Text] [Related]
14. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
15. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
16. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
17. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
19. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
Pryzbylkowski P; Obajimi O; Keen JC
Breast Cancer Res Treat; 2008 Sep; 111(1):15-25. PubMed ID: 17891453
[TBL] [Abstract][Full Text] [Related]
20. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
